Article
RING domain-deficient BRCA1 promotes PARP inhibitor and platinum resistance.
The Journal of clinical investigation - 1 Aug 2016
Wang Yifan, Krais John J, Bernhardy Andrea J, Nicolas Emmanuelle, Cai Kathy Q, Harrell Maria I, Kim Hyoung H, George Erin, Swisher Elizabeth M, Simpkins Fiona, Johnson Neil
Abstract excerpt
Patients with cancers that harbor breast cancer 1 (BRCA1) mutations initially respond well to platinum and poly(ADP-ribose) polymerase inhibitor (PARPi) therapy; however, resistance invariably arises in these patients and is a major clinical problem. The BRCA1185delAG allele is a common inherited mutation located close to the protein translation start site that is thought to produce a shortened, nonfunctional...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.